Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2014 16:15 ET | Source: MacroGenics, Inc.

MacroGenics Announces Pre-clinical Data to be Presented at ASH 2014 Annual Meeting

ROCKVILLE, Md., Nov. 6, 2014 (GLOBE NEWSWIRE) -- ROCKVILLE, Md., November 6, 2014 - MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing...
October 30, 2014 17:00 ET | Source: MacroGenics, Inc.

MacroGenics to Present Pre-Clinical Data on MGD006 at 26th EORTC-NCI-AACR Symposium

Rockville, MD, Oct. 30, 2014 (GLOBE NEWSWIRE) -- MacroGenics to Present Pre-Clinical Data on MGD006 at 26th EORTC-NCI-AACR Symposium ROCKVILLE, Md., October 30, 2014 - MacroGenics, Inc....
October 28, 2014 17:00 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of Third Quarter 2014 Financial Results Conference Call

ROCKVILLE, Md., October 28, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Tuesday, November 11, 2014, the Company will release its financial results for the quarter...
September 29, 2014 19:00 ET | Source: MacroGenics, Inc.

MacroGenics and Takeda Enter Second Strategic Alliance to Develop Multiple Additional DART Therapeutics

ROCKVILLE, Maryland and OSAKA, Japan, Sept. 29, 2014 (GLOBE NEWSWIRE) -- ROCKVILLE, Maryland and OSAKA, Japan - September 29, 2014 - MacroGenics, Inc. (NASDAQ: MGNX) and Takeda Pharmaceutical...
August 06, 2014 16:10 ET | Source: MacroGenics, Inc.

MacroGenics to Present at the Wedbush 2014 Life Sciences Management Access Conference

ROCKVILLE, Md., Aug. 6, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based...
August 05, 2014 16:05 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and Second Quarter 2014 Financial Results

ROCKVILLE, Md., Aug. 5, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based...
July 29, 2014 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of Second Quarter 2014 Financial Results Conference Call

ROCKVILLE, Md., July 29, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Tuesday, August 5, 2014, the Company will release its financial results for the quarter ended...
July 24, 2014 17:17 ET | Source: MacroGenics, Inc.

MacroGenics' DART Candidate IND for Colorectal Cancer, MGD007, Cleared to Start Enrolling Patients

ROCKVILLE, Md., July 24, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical stage biopharmaceutical company focused on discovering and identifying innovative monoclonal...
June 19, 2014 07:00 ET | Source: MacroGenics, Inc.

MacroGenics Initiates Phase 1 Study of MGD006 for the Treatment of Acute Myeloid Leukemia

ROCKVILLE, Md., June 19, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal...
May 27, 2014 08:00 ET | Source: MacroGenics, Inc.

MacroGenics and Takeda Enter Strategic Alliance to Develop DART for Treatment of Autoimmune Disorders

Option-based collaboration around MGD010 product candidate Incorporates MacroGenics' proprietary DART technology for bi-specific targeting of CD32B and CD79B MacroGenics has option to...